Cardiff Oncology (Cardiff Oncology) Net Issuance of Debt : $0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 1997. Start your Free Trial

What is Cardiff Oncology Net Issuance of Debt?

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. Cardiff Oncology's net issuance of debt for the three months ended in Dec. 2023 was $0.00 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.

Cardiff Oncology Net Issuance of Debt Historical Data

The historical data trend for Cardiff Oncology's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiff Oncology Net Issuance of Debt Chart

Cardiff Oncology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Issuance of Debt

Get a 7-Day Free Trial

Cardiff Oncology Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Issuance of Debt	Get a 7-Day Free Trial															-	-	-	-	-

Cardiff Oncology Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Cardiff Oncology Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Cardiff Oncology's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Cardiff Oncology (Cardiff Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardiff Oncology Inc (NAS:CRDF) » Definitions » Net Issuance of Debt

Comparable Companies

Traded in Other Exchanges

XE7C:Germany

Address

11055 Flintkote Avenue, San Diego, CA, USA, 92121

Website

https://www.cardiffoncology.com

Cardiff Oncology Inc is a clinical-stage, biotechnology company, developing treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, pancreatic cancer, metastatic castrate-resistant prostate cancer and leukemias.

Executives

Gary W Pace	director	C/O RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Fairooz Kabbinavar	officer: Chief Medical Officer	C/O TOCAGEN INC., 4242 CAMPUS POINT COURT, STE. 500, SAN DIEGO CA 92121
Mark Erlander	officer: Chief Scientific Officer	C/O TROVAGENE, INC., 11055 FLINTKOTE AVENUE, SUITE A, SAN DIEGO CA 92121
Lale White	director	310 GODDARD, SUITE 150, IRVINE CA 92618
James O Armitage	director	C/O TESARO, INC., 1000 WINTER ST., SUITE 3300, WALTHAM MA 02451
James E. Levine	officer: Chief Financial Officer	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Renee P Tannenbaum	director	9220 KIRBY DRIVE, SUITE 500, HOUSTON TX 77054
Tod Smeal	officer: Chief Scientific Officer	11055 FLINTKOTE AVENUE, SA DIEGO CA 92121
Katherine L Ruffner	officer: Chief Medical Officer	11055 FLINTKOTE AVENUE, SAN DIEGO CA 92121
Mani Mohindru	director	C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, STAMFORD CT 06902
Rodney S Markin	director	C/O UNIVERSITY OF NEBR MEDICAL CENTER, 983135 NEBRASKA MEDICAL CENTER, OMAHA NE 68198-3135
Gary S Jacob	director
Vicki Kelemen	officer: Exec. VP and COO	11055 FLINTKOTE AVENUE, SAN DIEGO CA 92121
John P Brancaccio	director	C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Rajeev M. Shah	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116